Dexrazoxane: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Dexrazoxane. Educational only — not medical advice.
Labeled uses
Dexrazoxane for injection is indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m 2 and who will continue to receive doxorubicin therapy to maintain tumor control. Do not use with the initiation of doxorubicin therapy [see Warnings and Precautions ( 5.2 )] .
Source: FDA labeling via NIH DailyMed (set c1d98fbe…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.